15
total announcements
543998.BO · 15 min delayed
Valiant Laboratories Ltd
Valiant Laboratories Ltd has announced the completion of dispatch of its Annual Report for FY 2025-26 and Notice of 5th Annual General Meeting to be held on September 28, 2026, through Video Conferencing.
Valiant Laboratories Ltd
Valiant Laboratories Ltd has received a credit rating of IND BBB/Stable/IND A2 for its bank loan facilities from India Ratings and Research (Ind-Ra).
Valiant Laboratories Ltd
Valiant Laboratories Ltd has dispatched letters to shareholders who had not registered their email addresses, informing them about the Annual Report for the Financial Year 2025-26 and the Notice of the 5th Annual General Meeting. The documents are available on the company's website and on stock exchange websites.
Valiant Laboratories Ltd
Valiant Laboratories Ltd has announced its 5th Annual General Meeting (AGM) and Annual Report for FY 2025-26. The AGM will be held on September 28, 2026, through Video Conferencing / Other Audio Visual Means. The Annual Report is available on the company's website.
Valiant Laboratories Ltd
Valiant Laboratories Ltd has released its Annual Report for FY 2025-26, which includes the Notice of the 5th Annual General Meeting (AGM) scheduled for September 28, 2026. The report highlights the company's expansion of manufacturing capacity, commercialization of Valiant Advanced Sciences, and investments in quality, operational excellence, and responsible business practices.
Valiant Laboratories Ltd
Valiant Laboratories Ltd has announced the 5th Annual General Meeting (AGM) through Video Conferencing/Other Audio Visual Means (VC/OAVM) on September 28, 2026, at 11:30 AM (IST). The meeting will be conducted in accordance with the Ministry of Corporate Affairs and SEBI circulars. Members will receive the notice and annual report through electronic mode, and the report will also be available on the company's website and stock exchanges' websites.
Valiant Laboratories Ltd
Valiant Laboratories Ltd has announced its standalone and consolidated audited financial results for the quarter ended June 30, 2026, with total income from operations at ₹74,273.37 crore and net profit after tax at ₹9,478.8 crore.
Valiant Laboratories Ltd
Valiant Laboratories Ltd has received a Monitoring Agency Report from India Ratings and Research Private Limited for the quarter ended June 30, 2026, stating that the proceeds from the Rights Issue have been utilized appropriately for the objects mentioned in the offer document.
Valiant Laboratories Ltd
Valiant Laboratories Ltd has announced the opening of a new corporate office, re-appointment of Managing Director and Independent Director, continuation of Non-Executive Non-Independent Director, and additional investment in a subsidiary.
Valiant Laboratories Ltd
Valiant Laboratories Ltd has announced the re-appointment of its Managing Director, Mr. Santosh Vora, and Independent Director, Mrs. Sonal Vira, for a further period. The company has also approved the continuation of directorship of Mr. Shantilal Vora, a Non-Executive Non-Independent Director. Additionally, the company has shifted its Registered Office and opened a new Corporate Office.
Valiant Laboratories Ltd
Valiant Laboratories Ltd has announced the re-appointment of its Managing Director, Mr. Santosh Vora, and Independent Director, Mrs. Sonal Vira, for a further period of five years. The company has also approved the continuation of directorship of Mr. Shantilal Vora as a Non-Executive Non-Independent Director. Additionally, the company has approved an investment of up to Rs. 60 Crore in its wholly-owned subsidiary, Valiant Advanced Sciences Private Limited.
Valiant Laboratories Ltd
Valiant Laboratories Ltd has announced the re-appointment of its Managing Director, Mr. Santosh Vora, and Independent Director, Mrs. Sonal Vira, for a further period of five years, subject to shareholder approval. The company has also approved the continuation of directorship of Mr. Shantilal Vora as a Non-Executive Non-Independent Director. Additionally, the company has approved the opening of a new corporate office and the shifting of its registered office to a new location.
Valiant Laboratories Ltd
Valiant Laboratories Ltd has announced its audited standalone and consolidated financial results for the quarter ended June 30, 2026, with the Board of Directors taking note of the audit report issued by Raman S. Shah & Co. The results are in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Valiant Laboratories Ltd
Valiant Laboratories Ltd has announced its audited standalone and consolidated financial results for the quarter ended June 30, 2026. The company's board of directors has considered and approved the results, and the statutory auditor has issued a report. The results are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and give a true and fair view of the company's net profit/loss and other comprehensive income.
Valiant Laboratories Ltd
Valiant Laboratories Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 10/08/2026 to consider and approve financial results for the quarter ended June 30, 2026.